Sarep­ta dis­con­tin­ues work on next-gen ex­on-skip­ping drug for Duchenne

Sarep­ta Ther­a­peu­tics is stop­ping de­vel­op­ment of vesleteplirsen, an ex­per­i­men­tal ex­on 51-skip­ping ther­a­py for Duchenne mus­cu­lar dy­s­tro­phy pa­tients with cer­tain mu­ta­tions.

It’s al­so halt­ing work on …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER